Innoviva, Inc. (INVA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$20.66-1.90%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Innoviva, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	118.42M
EPS	—	0.522
Annual ending 2026-12-31
Revenue	—	451.29M
EPS	—	2.42
Annual ending 2027-12-31
Revenue	—	490.01M
EPS	—	2.262

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Net income remains above $160 million annually	Net income rose from $20M to $186M in recent quarters.	Intact	Net income falls below $20 million in any quarter	Net income: $-83.42M FY2026-Q2; GAAP. Published target: >= $160 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-83,420,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c8242a4-ed75-4c04-adc1-46ed461f5293. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful launch and commercialization of NUZOLVENCE in H2 2026	The company plans to launch NUZOLVENCE in late 2026.	Intact	NUZOLVENCE launch delayed beyond 2026 or fails to gain market traction	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. NUZOLVENCE received FDA approval in December 2025 and management has consistently stated plans to commercialize it in the second half of 2026. No revenue yet reported from NUZOLVENCE, so delivery is pending but on track. Delivery assessment Oct 24, 2026
Total revenue grows to at least $440 million in FY26	A primary condition in Innoviva, Inc.'s published investment case. The stated target is >= $440 million.	Broken	Total revenue falls below $296 million in FY25	Revenue: $119.591M FY2026-Q2; GAAP. Published target: >= $440 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026119,591,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c8242a4-ed75-4c04-adc1-46ed461f5293. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.49B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$486,064,400	1 / 5
2026-07-25	Unavailable	Unavailable	2 / 3
2026-07-26	Unavailable	$486,064,400	1 / 5
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	Unavailable	Unavailable	2 / 3
2026-07-29	Unavailable	$486,064,400	1 / 5
2026-07-30	Unavailable	$486,064,400	1 / 5
2026-07-31	Unavailable	$486,064,400	1 / 5
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	$486,064,400	1 / 5
2026-08-03	Unavailable	$486,064,400	1 / 5
2026-08-04	Unavailable	$486,064,400	1 / 5
2026-08-05	Unavailable	$486,064,400	1 / 5
2026-08-06	Unavailable	$486,064,400	1 / 5
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	$490,697,400	1 / 5
2026-08-09	Unavailable	$490,697,400	1 / 5
2026-08-10	Unavailable	$490,697,400	1 / 5
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	4	1
2026-06-01	3	1
2026-07-01	3	1
2026-08-01	3	1
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Net income remains above $160 million annuallyNet income: $-83.42M
Successful launch and commercialization of NUZOLVENCE in H2 2026Qualitative condition
Total revenue grows to at least $440 million in FY26Published status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.0%Typical daily move · historical

Downside history

-16.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Innoviva, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-focused healthcare business with cyclical risk, rather than a proven durable compounder. The long-term thesis is intact: recent financial performance is in the top half of its industry, though earnings quality is neutral and confidence in the evidence is medium.

What's priced into Innoviva, Inc.

The valuation evidence describes INVA as cheap versus peers, while the expectations gap is negative, suggesting expectations are not especially demanding. The priced-in assessment is justified with low fragility, although the valuation measure rose recently and that change adds some context to the value case.

What the fundamentals likely do

Near term, recent earnings beats and strong IST U.S. sales growth support the business trajectory. Management remains on track with its 2026 IST sales goal and planned NUZOLVENCE launch, but NUZOLVENCE has not yet reported revenue and broader revenue growth remains a watch item. The next results carry meaningful execution risk, with a 41% estimated miss probability in the evidence.

What Innoviva, Inc. hinges on

The multi-year view depends partly on continued IST sales growth and delivery of the planned NUZOLVENCE commercialization. A guidance cut would be a meaningful negative, while continued strength from healthcare peers could support sector momentum. Weakening jobs data could raise recession concerns and weigh on cyclical healthcare names.